Heat Biologics: Up ahead of data presentation at cancer society meeting

Scorpius Holdings

20/05/2021 16:19

** Shares of drug developer  HTBX.O  up ~4% to $6.5 
    ** Co to present latest data on co's lead product candidate,
HS-110, at the virtual American Society of Clinical Oncology
Annual Meeting in June  urn:newsml:reuters.com:*:nGNX9sRdsG
    ** Mid-stage trial of HS-110 in combo with Bristol-Myers
Squibb's  BMY.N  Opdivo has completed enrollment in previously
treated patients with advanced non-small cell lung cancer
 urn:newsml:reuters.com:*:nGNX9sRdsG
    ** Up to Wednesday's close, HTBX up ~16% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))